Solid Biosciences (SLDB) Accounts Payables: 2017-2024
Historic Accounts Payables for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $3.5 million.
- Solid Biosciences' Accounts Payables rose 82.19% to $3.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.5 million, marking a year-over-year increase of 82.19%. This contributed to the annual value of $2.0 million for FY2023, which is 37.25% down from last year.
- As of Q3 2024, Solid Biosciences' Accounts Payables stood at $3.5 million, which was up 37.17% from $2.5 million recorded in Q2 2024.
- Over the past 5 years, Solid Biosciences' Accounts Payables peaked at $5.6 million during Q1 2023, and registered a low of $1.7 million during Q1 2024.
- Its 3-year average for Accounts Payables is $3.5 million, with a median of $3.2 million in 2022.
- Data for Solid Biosciences' Accounts Payables shows a peak YoY increase of 82.19% (in 2024) and a maximum YoY decrease of 69.08% (in 2024) over the last 5 years.
- Over the past 5 years, Solid Biosciences' Accounts Payables (Quarterly) stood at $3.3 million in 2020, then soared by 36.32% to $4.5 million in 2021, then decreased by 27.45% to $3.2 million in 2022, then tumbled by 37.25% to $2.0 million in 2023, then skyrocketed by 82.19% to $3.5 million in 2024.
- Its Accounts Payables stands at $3.5 million for Q3 2024, versus $2.5 million for Q2 2024 and $1.7 million for Q1 2024.